Biochemically produced sandalwood oil
Patent Information
- Application Number
- IN202217032468
- Authority / Receiving Office
- IN · IN
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2019-12-23
- Filing Date
- 2022-06-07
- Publication Date
- 2026-07-15
- Estimated Expiration
- 2040-12-22
AI Technical Summary
The high demand for sandalwood oil has led to over-harvesting and exploitation of sandalwood trees, resulting in unsustainable practices and environmental concerns, as traditional methods of extraction are energy-intensive and often use detrimental solvents, threatening the species' conservation.
Biochemically produced sandalwood oil is created using genetically engineered organisms capable of producing sesquiterpene synthases and cytochrome P450s, which convert FPP into sandalwood oil compounds, offering a sustainable alternative with enhanced santalol and bergamotol content.
This method provides a commercially viable, environmentally friendly sandalwood oil with higher santalol and bergamotol proportions, reducing the need for tree harvesting and minimizing environmental impact while maintaining the oil's olfactory quality.
Abstract
Description
BIOCHEMICALLY PRODUCED SANDALWOOD OILTechnical FieldThe present invention relates to the field of perfumery. More particularly, it concerns a biochemically produced sandalwood oil, as defined herein. Moreover, the present invention comprises the use of the biochemically produced sandalwood oil as part of a perfuming composition or of a perfuming consumer produce. The present invention comprises the use of the biochemically produced sandalwood oil as an anti-microbial and anti-inflammatory agent, and also as an arthropod control composition.BackgroundSandalwood oil, distilled from the heart wood and roots of the sandalwood tree, is one of the most valuable essential oils, valued by perfumers for its woody notes, providing a deep rich base note to perfumes and acting as a natural fixative. In addition to acting as a feed stock for the production of the essential oil, the wood is also valued for carving, and furniture making. Rising demand and very high prices for both wood and essential oil, a slow growing tree which takes 30 to 60 years to give a crop, a destructive harvest to get at the roots and heartwood with no sustainable harvesting options, and the scene is set for uncontrolled and illegal harvesting and destruction of the natural resource. 40 years ago sandalwood oil was sold at under US$100 / kg; today its market value is over US$2, 000 / kg reflecting the constraint to supplySandalwood oils come from a range of species, and while they all have similar uses, quality and characteristics vary between the oils of the different species. The key species used for distillation of essential oils are listed below, with East Indian Sandalwood oil and Australian Sandalwood oil dominating supplies to the market: East Indian Sandalwood oil (Santalum album) is the most well-known and oldest traded type of sandalwood, and has been in use for thousands of years. Cultivation centered in India (it is native to the highlands of southern India and the Malayan Archipelago) with the center of production in India in Mysore. Its natural distribution extends down to Indonesia (particularly Timor), and it has been introduced into Australia and plantations established in the tropical northwestern areas - an estimated 8,000 ha with annual additions of around 1,000 ha; more recently it has also been introduced into a number of the S Pacific Islands and plantations established (Fiji, Tonga, Vanuatu, New Caledonia); Australian Sandalwood oil (Santalum spicatum, syn. Eucarya spicata (also referred to as West Australian Sandalwood oil) is native to the desert-like areas of SW Australia, close to Perth. Substantial plantations have also now been established - around 15,000 ha with annual additions of 1-2,000 ha. A second sandalwood species, S. lanceo latum, is also found in Australia, principally in Queensland, NSW, and northwestern part of Western Australia, but is little used commercially. Santalum paniculatum. Only found in Hawaii. Around 7,000 ha reported to be under sustainable management. Commercial oil now coming onto the market. Santalum yasi. Found in Fiji, Samoa and Tonga. Traditionally included in mixed cropping agroforestry cultivation systems. The species hybridizes readily with S. album resulting in variable quality of oil depending on the source trees.Heartwood and roots are chipped and pulverized to a coarse grind before distillation. Oil yield varies with the plant part, the age of the tree and the environment of cultivation. Roots can give up to 10% oil; heartwood up to 4%. Distillation takes 48 to 72 hours, and effectively ends when the yield of oil ceases to be economical. High pressure steam distillation will give a higher yield and reduced distillation time but will lose some of the delicate notes.A rise in the number of working populations in the developing economies has led to increased stress levels, which inclines consumers toward spas for relaxation. This ultimately has a positive impact on the sandalwood oil market since it is a widely used essential oil for aromatherapy. Increase in demand for natural perfume over synthetic perfume is a major driver for the sandalwood oil market With rise in disposable income of the population, there is an escalation in the demand for personal care products such as aromatic soaps, shampoos, and lotions, which drives the growth of the market. However, high price of sandalwood oil is expected to hinder the growth of the sandalwood oil market.Unfortunately, because of the high value placed on sandalwood products, especially on sandalwood oil, the sandalwood tree has a long history of exploitation. High demand for the tree's valuable oil has resulted in over-harvesting, and consequently, the sandalwood tree is one of the most exploited groups of plants across its range. Today, many sandalwood species are considered “vulnerable” by the IUCN.Hence there is a need for alternative means of preparing sandalwood oils which can be used for the commercial uses mentioned above.Summary of the inventionThe present invention provides a biochemically produced sandalwood oil.An aspect of the invention provides a biochemically produced sandalwood oil comprising at least 85% santalol and bergamotol and 1% or less cis-lanceol, wherein the oil has one or more of the following features: i) 5% or less alpha- santalal, ii) 5% or less farnesol; iii) 0.5% or less spirosantalol.An embodiment of this aspect of the invention is wherein the 85% santalol and bergamotol comprises 37-65% alpha- santalol, 13-37% beta- santalol and 1 to 35% bergamotol.An embodiment of this aspect of the invention is wherein the ratio of cis- alpha- santalol to trans-alpha-santalol is 90: 1 or less.An embodiment of this aspect of the invention is wherein the alpha- santalal is 90% or more trans- alpha- santalal.An embodiment of this aspect of the invention is wherein the biochemically produced sandalwood oil comprises 0-1% cis-beta- sinensol.An embodiment of this aspect of the invention is wherein the biochemically produced sandalwood oil comprises: i) 50-60% alpha- santalol, ii) 20-35% beta- santalol; iii) 5% or less alpha- santalal; iv) 5% or less farnesol; v) 5% or less spirosantalol; vi) 4-10% bergamotol; vii) 0-5% cis-beta- sinensol; viii) 5% or less epi-beta- santalol.An embodiment of this aspect of the invention is wherein the biochemically produced sandalwood oil comprises: i) 54%-59% alpha- santalol; ii) 25.1%-30% beta- santalol; iii) 0.7% -3% alpha- santalal; iv) 1% -2.3% farnesol; v) 0.5% or less spirosantalol; vi) 6.3%- 7.2% bergamotol; vii) 0.6% - 1.4% cis-beta- sinensol; viii) l%-2% epi-beta- santalol.An embodiment of this aspect of the invention is wherein the biochemically produced sandalwood oil is microbially produced.An embodiment of this aspect of the invention is wherein the biochemically produced sandalwood oil is encapsulated within a matrix material.An aspect of the invention provides a method of preparing the biochemically produced sandalwood oil the invention comprising (i) cultivating a genetically engineered organism capable of producing FPP and which expresses a suitable sesquiterpene synthase, a cytochrome P450 and a CPR, and (ii) isolating the biochemically produced sandalwood oil of the invention.An aspect of the invention provides a perfuming composition comprising: i) the sandalwood oil of the invention; ii) at least one ingredient selected from the group consisting of a perfumery carrier and a perfumery base; and iii) optionally at least one perfumery adjuvant.An aspect of the invention provides a perfumed consumer product comprising the biochemically produced sandalwood oil or perfuming composition of the invention.An embodiment of this aspect of the invention is wherein the perfumery consumer product is a perfume, a fabric care product, a body-care product, a cosmetic preparation, a skin-care product, an air care product or a home care product or wherein the perfumery consumer product is a fine perfume, a splash or eau de perfume, a cologne, a shave or an after-shave lotion, a liquid or solid detergent, a fabric softener, a fabric refresher, an ironing water, a paper, a bleach, a carpet cleaner, curtain-care products, a shampoo, a coloring preparation, a color care product, a hair shaping product, a dental care product, a disinfectant, an intimate care product, a hair spray, a vanishing cream, a deodorant or antiperspirant, hair remover, tanning or sun product, nail products, skin cleansing, a makeup, a perfumed soap, shower or bath mousse, oil or gel, or a foot / hand care products, a hygiene product, an air freshener, a “ready to use” powdered air freshener, a mold remover, furnisher care, wipe, a dish detergent or hard-surface detergent, a leather care product, a car care product.An aspect of the invention provides a sandalwood oil of the invention for use in the treatment of a microbial infection, an inflammatory condition and / or increase skin moisturizing, or for use in the treatment of acne, eczema, psoriasis, seborrheic or atopic dermatitis.An aspect of the invention provides an arthropod control composition comprising the sandalwood oil of the invention.Brief description of the figuresFigure 1: GCMS analysis of the molecules produced by E. Coli engineered to produced sesquiterpenes and expressing an alpha-santalene / beta-santalene synthase (SaSAS), cytochrome P450 reductase (CPRm) and a cytochrome P450 monooxygenase SaCP816. A. Total sesquiterpene mixture obtained after solvent extraction of the culture medium. B. Oxygenated sesquiterpene fraction obtained after an additional purification step. 1, α-santalene; 2, α-trans-bergamotene; 3, epi-β-santalene; 4, β-santalene; 5, (Z)-α-santalol; 6, (Z)-α- trans-bergamotol; 7, (Z)- epi-β- santalol ; 8, (Z)-β-santalol.Figure 2: Workflow for the measurement of cytokines release by NHDF and NHEK cells under pro-inflammatory challenge.Figure 3: Viability of NHDF (A) and NHEK (B and C) cells under different pro-inflammatory challenges when treated with sandalwood oil of the invention and S. album essential oil for 26 hours. Cell viability was measured using the standard MTS assay. Each condition was measured in triplicate. In all panels - columns 4 and 5 are ibuprofen; columns 6 to 10 are sandalwood oil of the invention; columns 11 to 15 are S. album essential oil.Figure 4: Viability of NHEK cells under basal culturing conditions when exposed to sandalwood oil of the invention for 24 and 72 hours. Cell viability was measured using the standard MTS assay, with each condition performed in triplicate.Figure 5: Dose-response of sandalwood oil of the invention on ticks repellency (Ixodes ricinus ) using a test adapted from Krober T. et al. Pesticide Biochemistry and Physiology. 2013; 107(2): 160-168.Figure 6: Dose-response of sandalwood oil of the invention on mosquito repellency (A. aegyptii), measured using the Warm Body Assay as described by Krober T. et al. J. of the American Mosquito Control Association (2010), 26 (4):381-386.Figure 7: Effect the transcription of selected mRNAs in NHEKs cells treated with sandalwood oil of the invention at 10, 20 and 40 μg / mlFigure 8: Effect of sandalwood oil of the invention at 20 and 40 μg / ml on protein expression in NHEKs cells at 24 and 72 hrs (Figures 8A and 8B, respectively)Figure 9: Effect of sandalwood oil of the invention at 20 and 40 μg / ml on biotin diffusion in Reconstituted Human EpidermisFigure 10: Effect of sandalwood oil of the invention at 20 and 40 μg / ml on the expression levels of loricrin, involucrin and hyaluronan synthase 3 in a reconstituted human epidermis model mimicking sensitive skinDescription of the inventionIn the context of the descriptions provided herein and of the appended claims, the use of ‘or” means“and / or” unless stated otherwise.Similarly, “comprise,” “comprises,” “comprising”, “include,” “includes,” and “including” are interchangeable and not intended to be limiting.The term“about” indicates a potential variation of ± 25% of the stated value, in particular ± 15%, ±10 %, more particularly ± 5%, ± 2% or ± 1%.The term "substantially" describes a range of values of from about 80 to 100%, such as, for example, 85-99.9%, in particular 90 to 99.9%, more particularly 95 to 99.9%, or 98 to 99.9% and especially 99 to 99.9%.“Predominantly” refers to a proportion in the range of above 50%, as for example in the range of 51 to 100%, particularly in the range of 75 to 99.9%; more particularly 85 to 98.5%, like 95 to 99%.The biochemically produced sandalwood oil of the invention may comprise the following compounds.cis-alpha-santalol, (+)-cis-alpha- santalol (alpha(2Z)-santalol), (±)-(2Z)-5-[(1S,3R,4R)-2,3-dimethyltricyclo[2.2.1.0~2,6~]hept-3-yl]-2-methyl-2-penten-1 -ol.trans-alpha- santalol, (+) -trans-alpha- santalol (alpha(2E)-santalol), (2E)-5-[(3S)-2,3-dimethyltricyclo[2.2.1 ,0~2,6~]hept-3-yl]-2-methyl-2-penten-1 -ol.cis-beta- santalol, (-)-cis-beta- santalol (beta (2Z)-santalol), (-)-(2Z)-2-methyl-5-[(1S,2R,4R)-2-methyl-3-methylenebicyclo[2.2.1]hept-2-yl]-2-penten-1-ol.trans-beta- santalol, (-)-trans-beta- santalol (beta (2E)-santalol), (E)-2-methyl-5-((1RS,2SR,4SR)-2-methyl-3-methylenebicyclo[2.2.1]heptan-2-yl)pent-2-en-1-ol.cis-lanceol, (-)- cis-lanceol, 2,6-Heptadien-1 -ol, 2-methyl-6-[(1 S)-4-methyl-3-cyclohexen-1 -yl]-, (2 Z)-.cis-alpha- santalal (alpha- santalal (Z)-), (+)-(2Z)-5-[(3R)-2,3-dimethyltricyclo[2.2.1 ,0~2,6~]hept-3-yl]-2-methyl-2-pentenal.trans-alpha- santalal (alpha- santalal, (E)-), (+)-(2E)-5-[(3R)-2,3-dimethyltricyclo[2.2.1 ,0~2,6~]hept-3-yl]-2-methyl-2-pentenal.spirosantalol, Spiro[bicyclo[2.2.1]heptane-2,l'-cyclopentane]-3'-ethanol, β,3-bis(methylene)-.farnesol , (2E,6E)-farnesol, (2E,6E)-3,7,11 -trimethyl-2, 6, 10-dodecatrien-1-ol, CAS number 106-28-5trans-beta- santalal, (2E)-2-methyl-5-[(1S,2R,4R)-2-methyl-3-methylenebicyclo[2.2.1]hept-2-yl]-2-pentenal.bergamotol , (-)-(Z)-alpha-bergamotol, (-)-(Z)-5-((1S,5S,6R)-2,6-dimethylbicyclo[3.1.1]hept-2-en-6-yl)-2-methylpent-2-en- 1 -ol.The following components can also be present in the biochemically produced sandalwood oil of the invention.(1S,2R,4S,7R)-1,7-dimethyl-7-(4-methyl-3-penten-1-yl)bicyclo[2.2. l]heptan-2-ol.epi-beta- santalol, (Z)-epi-beta- santalol, (2Z)-2-methyl-5-[(1S,2R,4R)-2-methyl-3-methylenebicyclo[2.2.1 ]hept-2-yl]-2-pentenal.Dihydro- alpha-santalol 5-[(3R)-2,3-dimethyltricyclo[2.2.1.0~2,6~]hept-3-yl]-2-methyl-1 -pentanol. cis-beta- sinensol, (2Z,6E)-2, 6-dimethyl- 10-methylidene-2, 6, 11-dodecatrien-1-ol,5-(2,3-dimethyltricyclo[2.2.1.02,6]heptan-3-yl)pent-3-en-2-one.2,3-dimethyl-3-(4-methyl-3-penten-1-yl)bicyclo[2.2.1]heptan-2-ol.(E,Z)- beta- sinensol, 2,6,11-Dodecatrien-1-ol, 2,6-dimethyl- 10-methylene-, ( E,Z )-.(2E,6E)-beta-sinensol 2,6,11-Dodecatrien-1-ol, 2,6-dimethyl- 10-methylene-, (2E,6E)-. alpha- santalene, alpha-santalene, (7R)-1,7-dimethyl-7-(4-methyl-3-penten-1-yl) tricyclo[2.2.1.0-2, 6~] heptane.alpha- farnesene, (z;z)-alpha- farnesene, (3Z,6Z)-3,7,11 -trimethyl- 1,3, 6, 10-dodecatetraene.(-)-beta- santalene isomer, (1S,2R,4R)-2-methyl-3-methylidene-2-(4-methyl-3-penten-1-yl)bicyclo[2.2.1]heptane.beta-santalene (1S,2R,4R)-2-methyl-3-methylidene-2-(4-methyl-3-penten-1-yl)bicyclo[2.2.1 ]heptane.alpha- curcumene, (+ / -)- alpha-curcumene, 4- (1 , 5-DIMETHYL-4-HEXENYL)- 1 - METHYLBENZENE.beta-curcumene, (+-)-beta-curcumene, 1 -methyl-4-(6-methyl-5-hepten-2-yl)- 1 ,4-cyclohexadiene.The present invention provides a biochemically produced sandalwood oil comprising at least 85% santalol and bergamotol and 1% or less cis-lanceol, wherein the oil has one or more of the following features: i) 5% or less alpha- santalal, ii) 5% or less farnesol; iii) 0.5% or less spirosantalol.As used herein the term “biochemically produced” means that the sandalwood oil of the invention is not prepared from the sandalwood tree. Rather, the sandalwood oil is biochemically produced using organisms which have been genetically engineered to generate a biochemical pathway which leads to the production of sandalwood oil of the invention. An example of genes which can to provide such a biochemical pathway is provided herein. However it should be understood that the scope of the invention also includes sandalwood oils having the claimed chemical composition and provided using other biochemical pathways, including synthetic pathways genes isolated from other species, and genes modified to produce the chemical composition of the sandalwood oil of the invention.The invention provides a number of advantages over the prior known sandalwood oil.As outlined in the accompanying statement in the background to the invention, due to the high value placed on sandalwood oil, the sandalwood tree has a long history of exploitation. High demand for the tree's valuable oil has resulted in over-harvesting, and consequently, the sandalwood tree is one of the most exploited groups of plants across its range. This has resulted in the sandalwood species as being considered “vulnerable” by the IUCN.Moreover, existing methods of extracting sandalwood oil from trees requires the wood to be ground into a fine powder before the oil is extracted using a distillation process. Such methods are highly energy demanding and may also use solvents which are detrimental to the environment.The present invention overcomes these environmental and conservation issues since the oil is prepared using genetically engineered organisms. Indeed the biochemically produced sandalwood oil of the invention is the first sandalwood oil to ever be prepared to a commercially acceptable quality using such techniques.In addition to these clearly important environmental advantages, the sandalwood oil of the invention also has a number of surprising technical advantages over prior known sandalwood oil.One such surprising technical advantage is that the sandalwood oil of the invention has a higher proportion of santalol and bergamotol (at least 85%) to any prior known sandalwood oil. Santalol, comprising alpha and beta santalol, and bergamotol, are key olfactory components of sandalwood oil. Furthermore, the ratio of alpha and beta santalol in the sandalwood oil of the invention respects that of the prior known sandalwood oil and thus retains the characteristic odour of the oil.Another rising technical advantage is that the sandalwood oil of the invention has a 1% or less cis-lanceol. It is known in the art that this compound is nearly odourless (Baldovini et al (2011) Flavour and Fragrance Journal vol. 26, 7-26). Hence by having less of the odourless compound the sandalwood oil of the invention does not contain what is essentially a contaminating compound which adds no value to the overall olfactory quality of the oil.According the sandalwood oil of the invention has environmental advantages and surprising technical advantages over prior known sandalwood oil.Embodiments of each of the above aspects are described in further detail below. As the skilled person would understand, any features of an embodiment described which are broader than the corresponding feature in an above aspect do not apply to that aspect.The sandalwood oil of the invention comprises at least 85% santalol and bergamotol.By “at least 85% santalol and bergamotol” we include where there sandalwood oil of the invention comprises at least 85% santalol and bergamotol. In some embodiments the sandalwood oil comprises at least 86% santalol and bergamotol. In some embodiments the sandalwood oil comprises at least 87% santalol and bergamotol. In some embodiments the sandalwood oil comprises at least 88% santalol and bergamotol. In some embodiments the sandalwood oil comprises at least 89% santalol and bergamotol. In some embodiments thesandalwood oil comprises at least 90% santalol and bergamotol. In some embodiments the sandalwood oil comprises at least 91% santalol and bergamotol. In some embodiments the sandalwood oil comprises at least 92% santalol and bergamotol. In some embodiments the sandalwood oil comprises at least 93% santalol and bergamotol. In some embodiments the sandalwood oil comprises at least 94% santalol and bergamotol. In some embodiments the sandalwood oil comprises at least 95% santalol and bergamotol.By “santalol” we include alpha-santalol, beta- santalol and epi-beta- santalol. Information on the structure and characteristics of these compounds are provided herein. In one embodiment of the invention the sandalwood oil comprises comprises 37-65% alpha-santalol and 13-37% beta-santalol. The sandalwood oil can also comprise 5% or less epi-beta- santalolIn another embodiment of the invention the sandalwood oil comprises 37-65% alpha-santalol. In another embodiment of the invention the sandalwood oil comprises 40-65% alpha-santalol. In another embodiment of the invention the sandalwood oil comprises 45-65% alpha-santalol In another embodiment of the invention the sandalwood oil comprises 50-65% alpha-santalol In another embodiment of the invention the sandalwood oil comprises 55-65% alpha-santalol In another embodiment of the invention the sandalwood oil comprises 60-65% alpha-santalol In another embodiment of the invention the sandalwood oil comprises 37-60% alpha-santalol. In another embodiment of the invention the sandalwood oil comprises 37-55% alpha-santalol. In another embodiment of the invention the sandalwood oil comprises 37-50% alpha-santalol. In another embodiment of the invention the sandalwood oil comprises 37-45% alpha-santalol. In another embodiment of the invention the sandalwood oil comprises 37-40% alpha-santalol. In another embodiment of the invention the sandalwood oil comprises 40-60% alpha-santalol. In another embodiment of the invention the sandalwood oil comprises 45-60% alpha-santalol. In another embodiment of the invention the sandalwood oil comprises 50-60% alpha-santalol. In another embodiment of the invention the sandalwood oil comprises 50-59% alpha-santalol. In another embodiment of the invention the sandalwood oil comprises 51-59% alpha-santalol. In another embodiment of the invention the sandalwood oil comprises 52-59% alpha-santalol. In another embodiment of the invention the sandalwood oil comprises 53-59% alpha-santalol. In another embodiment of the invention the sandalwood oil comprises 54-59% alpha-santalol. Inanother embodiment of the invention the sandalwood oil comprises 20-37% beta- santalol. In another embodiment of the invention the sandalwood oil comprises 22-37% beta- santalol. In another embodiment of the invention the sandalwood oil comprises 24-37% beta- santalol. In another embodiment of the invention the sandalwood oil comprises 25-37% beta- santalol. In another embodiment of the invention the sandalwood oil comprises 20-35% beta- santalol. In another embodiment of the invention the sandalwood oil comprises 20-33% beta- santalol. In another embodiment of the invention the sandalwood oil comprises 20-31% beta- santalol. In another embodiment of the invention the sandalwood oil comprises 20-30% beta- santalol. In another embodiment of the invention the sandalwood oil comprises 22-30% beta- santalol. In another embodiment of the invention the sandalwood oil comprises 24-30% beta- santalol. In another embodiment of the invention the sandalwood oil comprises 25-30% beta- santalol. In another embodiment of the invention the sandalwood oil comprises 25.1-30% beta- santalol. In another embodiment of the invention the sandalwood oil comprises 0.5-10% epi-beta- santalol. In another embodiment of the invention the sandalwood oil comprises 1-4% epi-beta- santalol. In another embodiment of the invention the sandalwood oil comprises 1-3% epi-beta- santalol. In another embodiment of the invention the sandalwood oil comprises 1 -2% epi-beta- santalol.The sandalwood oil of the invention comprises at least 85% santalol and bergamotol.Information on the structure and characteristics of bergamotol is provided herein.In one embodiment of the invention the sandalwood oil comprises comprises 37-65% alpha-santalol and 13-37% beta- santalol and 1 to 35% bergamotol.In one embodiment of the invention sandalwood oil comprises 1 to 35% bergamotol. In one embodiment of the invention sandalwood oil comprises 1 to 34% bergamotol. In one embodiment of the invention sandalwood oil comprises 1 to 33% bergamotol. In one embodiment of the invention sandalwood oil comprises 1 to 32% bergamotol. In one embodiment of the invention sandalwood oil comprises 1 to 31% bergamotol. In one embodiment of the invention sandalwood oil comprises 1 to 30% bergamotol. In one embodiment of the invention sandalwood oil comprises 1 to 29% bergamotol. In oneembodiment of the invention sandalwood oil comprises 1 to 28% bergamotol. In one embodiment of the invention sandalwood oil comprises 1 to 27% bergamotol. In one embodiment of the invention sandalwood oil comprises 1 to 26% bergamotol. In one embodiment of the invention sandalwood oil comprises 1 to 25% bergamotol. In one embodiment of the invention sandalwood oil comprises 1 to 20% bergamotol. In one embodiment of the invention sandalwood oil comprises 1 to 15% bergamotol. In one embodiment of the invention sandalwood oil comprises 1 to 10% bergamotol. In one embodiment of the invention sandalwood oil comprises 2 to 8% bergamotol. In one embodiment of the invention sandalwood oil comprises 3 to 8% bergamotol. In one embodiment of the invention sandalwood oil comprises 4 to 8% bergamotol. In one embodiment of the invention sandalwood oil comprises 5 to 7.5% bergamotol. In one embodiment of the invention sandalwood oil comprises 5.5 to 7.5% bergamotol. In one embodiment of the invention sandalwood oil comprises 6 to 7.4% bergamotol. In one embodiment of the invention sandalwood oil comprises 6.2 to 7.3% bergamotol. In one embodiment of the invention sandalwood oil comprises 6.3 to 7.2% bergamotol.The present invention provides a biochemically produced sandalwood oil comprising at least 85% santalol and bergamotol and 1% or less cis-lanceol. Information on the structure and characteristics of cis-lanceol is provided herein.In one embodiment of the invention sandalwood oil comprises 0.9% or less cis-lanceol. In one embodiment of the invention sandalwood oil comprises 0.8% or less cis-lanceol. In one embodiment of the invention sandalwood oil comprises 0.7% or less cis-lanceol. In one embodiment of the invention sandalwood oil comprises 0.6% or less cis-lanceol. In one embodiment of the invention sandalwood oil comprises 0.5% or less cis-lanceol. In one embodiment of the invention sandalwood oil comprises 0.4% or less cis-lanceol. In one embodiment of the invention sandalwood oil comprises 0.3% or less cis-lanceol. In one embodiment of the invention sandalwood oil comprises 0.2% or less cis-lanceol. In one embodiment of the invention sandalwood oil comprises 0.2% or less cis-lanceol. In one embodiment of the invention sandalwood oil comprises 0.1% or less cis-lanceol. In one embodiment of the invention sandalwood oil comprises 0.05% or less cis-lanceol. In one embodiment of the invention sandalwood oil comprises 0.01% or less cis-lanceol. In one embodiment of the invention sandalwood oil comprises 0% cis-lanceol.In one embodiment the present invention provides a biochemically produced sandalwood oil comprising 5% or less alpha- santalal. Information on the structure and characteristics of alpha-santalal is provided herein.In one embodiment of the invention sandalwood oil comprises 4% or less alpha- santalal. In one embodiment of the invention sandalwood oil comprises 3% or less alpha- santalal. In one embodiment of the invention sandalwood oil comprises 2% or less alpha- santalal. In one embodiment of the invention sandalwood oil comprises 0.2% to 4% alpha- santalal. In one embodiment of the invention sandalwood oil comprises 0.4% to 4% alpha- santalal. In one embodiment of the invention sandalwood oil comprises 0.6% to 4% alpha- santalal. In one embodiment of the invention sandalwood oil comprises 0.2% to 3% alpha- santalal. In one embodiment of the invention sandalwood oil comprises 0.4% to 3% alpha- santalal. In one embodiment of the invention sandalwood oil comprises 0.6% to 3% alpha- santalal. In one embodiment of the invention sandalwood oil comprises 0.7% to 3% alpha- santalal.In one embodiment the present invention provides a biochemically produced sandalwood oil comprising 5% or less farnesol. Information on the structure and characteristics of farnesol is provided herein.In one embodiment of the invention sandalwood oil comprises 4% or less farnesol. In one embodiment of the invention sandalwood oil comprises 3% or less farnesol. In one embodiment of the invention sandalwood oil comprises 1% to 3% farnesol. In another embodiment of the invention sandalwood oil comprises 1% to 2.5% farnesol. In another embodiment of the invention sandalwood oil comprises 1% to 2.4% farnesol. In another embodiment of the invention sandalwood oil comprises 1% to 2.3% farnesol.In one embodiment the present invention provides a biochemically produced sandalwood oil comprising 0.5% or less spirosantalol. Information on the structure and characteristics of spirosantalol is provided herein.In one embodiment of the invention sandalwood oil comprises 0.5% or less spirosantalol. In one embodiment of the invention sandalwood oil comprises 0.4% or less spirosantalol. In one embodiment of the invention sandalwood oil comprises 0.3% or less spirosantalol. In one embodiment of the invention sandalwood oil comprises 0.2% or less spirosantalol. In one embodiment of the invention sandalwood oil comprises 0.1% or less spirosantalol. In one embodiment of the invention sandalwood oil comprises 0.05% or less spirosantalol. In one embodiment of the invention sandalwood oil comprises 0.01% or less spirosantalol. In one embodiment of the invention sandalwood oil comprises 0% spirosantalol.By “alpha-santalol” we include both cis- alpha- santalol and trans- alpha- santalol. Information on the structure and characteristics of these compounds are provided herein.One embodiment of the invention is wherein ratio of cis- alpha- santalol to trans- alpha- santalol is 90: 1 or less. One embodiment of the invention is wherein ratio of cis- alpha- santalol to trans-alpha- santalol is 85: 1 or less. In one embodiment of the invention is wherein ratio of cis- alpha-santalol to trans- alpha- santalol is 80: 1 or less. In one embodiment of the invention is wherein ratio of cis- alpha- santalol to trans- alpha- santalol is 78:1 or less. In one embodiment of the invention is wherein ratio of cis- alpha- santalol to trans- alpha- santalol is 75:1 or less. In one embodiment of the invention is wherein ratio of cis- alpha- santalol to trans- alpha- santalol is 72: 1 or less. In one embodiment of the invention is wherein ratio of cis- alpha- santalol to trans-alpha- santalol is 70: 1 or less. In one embodiment of the invention is wherein ratio of cis- alpha-santalol to trans- alpha- santalol is 68:1 or less. In one embodiment of the invention is wherein ratio of cis- alpha- santalol to trans- alpha- santalol is 66: 1 or less.By “ alpha - santalal” we include both cis- alpha- santalal and trans- alpha- santalal. Information on the structure and characteristics of these compounds are provided herein.One embodiment of the invention is wherein the alpha- santalal is 90% or more trans- alpha-santalal. One embodiment of the invention is wherein the alpha- santalal is 92% or more trans-alpha- santalal. One embodiment of the invention is wherein the alpha- santalal is 94% or more trans- alpha- santalal. One embodiment of the invention is wherein the alpha- santalal is 96% or more trans- alpha- santalal. One embodiment of the invention is wherein the alpha- santalal is 98% or more trans- alpha- santalal. One embodiment of the invention is wherein the alpha-santalal is 99% or more trans- alpha- santalal.In one embodiment the present invention provides a biochemically produced sandalwood oil comprising 2% or less cis-beta- sinensol. Information on the structure and characteristics of cis-beta- sinensol is provided herein.In one embodiment of the invention sandalwood oil comprises 0.1 -1.9% cis-beta- sinensol. In one embodiment of the invention sandalwood oil comprises 0.2-1.7% cis-beta- sinensol. In one embodiment of the invention sandalwood oil comprises 0.3-1.6% cis-beta- sinensol. In one embodiment of the invention sandalwood oil comprises 0.4-1.5% cis-beta- sinensol. In one embodiment of the invention sandalwood oil comprises 0.5-1.4% cis-beta- sinensol. In one embodiment of the invention sandalwood oil comprises 0.6-1.4% cis-beta- sinensol.In one embodiment of the invention sandalwood oil is wherein at least 85% santalol and bergamotol comprises 37-65% alpha- santalol, 13-37% beta- santalol and 1 to 35% bergamotol.In one embodiment of the invention the sandalwood oil comprises: i) 50-60% alpha- santalol, ii) 20-35% beta- santalol; iii) 5% or less alpha- santalal; iv) 5% or less farnesol; v) 0.5% or less spirosantalol; vi) 4-10% bergamotol; vii) 0-5% cis-beta- sinensol; viii) 5% or less epi-beta-santalol.In one embodiment of the invention the sandalwood oil comprises: i) 54%-59% alpha- santalol; ii) 25.1%-30% beta- santalol; iii) 0.7% - 3% alpha- santalal; iv) 1% -2.3% farnesol; v) 0.5% or less spirosantalol; vi) 6.3%- 7.2% bergamotol; vii) 0.6% - 1.4% cis-beta- sinensol; viii) 1-2% epi-beta- santalol.In addition to the compounds listed above, the biochemically produced sandalwood oil may comprise additional compounds. For example, (1S,2R,4S,7R)-1,7-dimethyl-7-(4-methyl-3-penten-1-yl)bicyclo[2.2. l]heptan-2-ol, epi-beta- santalol, 5-[(3R)-2,3-dimethyltricyclo[2.2.1 ,0~2,6~]hept-3-yl]-2-methyl-1 -pentanol, alpha-santalene, alpha- farnesene, beta- santalene isomer, beta- santalene, alpha-curcumene, beta-curcumene. Further additional compounds may also be included, not least those compounds discussed in Baldovini et al (2011) Flavour and Fragrance Journal vol. 26, 7-26.cis-beta- sinensol, (2Z,6E)-2,6-dimethyl-10-methylidene-2,6,ll-dodecatrien-1-ol and 2,3-dimethyl-3-(4-methyl-3-penten-1-yl)bicyclo[2.2.1]heptan-2-ol are new.Hence a further aspect of the invention provides cis-beta- sinensol ((2Z,6E)-2, 6-dimethyl- 10-methylidene-2,6, 11 -dodecatrien- 1 -ol).A further aspect of the invention provides 2,3-dimethyl-3-(4-methyl-3-penten-1-yl)bicyclo[2.2.1 ]heptan-2-ol.Preparation of the biochemically produced sandalwood oil of the inventionThe present invention provides a biochemically produced sandalwood oil. The sandalwood oil is produced from genetically engineered organisms. As stated above the biochemically produced sandalwood oil of the invention is the first sandalwood oil to ever be prepared to a commercially acceptable quality using such techniques.Sandalwood oil comprises different sesquiterpene alcohol compounds which contribute towards the olfactory property of the oil. The sesquiterpene alcohols are derived from terpene hydrocarbons in a multi-step enyzmic process. The enzymatic synthesis of sesquiterpene alcohol compounds is known in the art. In brief, farnesyl diphosphate (FPP) is converted into, amongst other compounds, alpha- and beta- santalene via sequiterpene synthases. They are subsequently converted tosesquiterpene alcohol compoundsvia cytochrome P450s.It can be appreciated that in order to prepare the biochemically produced sandalwood oil of the invention a genetically engineered organism can be used which expresses suitable sesquiterpene synthases and cytochrome P450s. Examples of such enzymes are known in the art. For example, WO2010067309 and WO2015040197 provide details of enzymes suitable for the preparation of the biochemically produced sandalwood oil of the invention. Further sesquiterpene synthases and cytochrome P450s may include those provided in the art. For example, Jones et al, Journal of biological chemistry (2011), 286(20), 17445-54 and Srivastava et al, Scientific Reports (2015), 5, 10095 provide details of sesquiterpene synthases while Celedon et al, Plant Journal (2016), 86(4), 289-29. provide details of cytochrome P450sMoreover, it is also known in the art that the presence of a cytochrome P450-reductase (CPR) is beneficial in order to reconstitute the activity of the cytochrome P450 enzyme. Examples of such CPRs are also known in the art. For example, WO2015040197 provide details of CPRs suitable for this process.As stated above, FPP is converted into sesquiterpenes via sesquiterpene synthases. It is possible that the biochemically produced sandalwood oil of the invention can be prepared using a method in which FPP is exogenously supplied to a suitable genetically engineered organism. However it is preferable that that organism is capable of producing FPP. Such an organism may produce FPP naturally or it does not produce FPP naturally but is transformed to produce FPP. Methods to transform organisms, for example microorganisms, so that they produce FPP are already known in the art. Such methods can for example be found in the literature, for example in the following publications: Martin, V.J., Pitera, D.J., Withers, S. T., Newman, J.D., and Keasling, J.D. Nat BiotechnoL, 2003, 21(7), 796-802 (transformation of E. coli); Wu, S., S chalk, M., Clark, A., Miles, R.B., Coates, R., and Chappell, J., Nat BiotechnoL, 2006, 24(11), 1441-1447 (transformation of plants); Takahashi, S., Yeo, Y., Greenhagen, B. T., McMullin, T., Song, L., Maurina-Brunker, J., Rosson, R., Noel, J., Chappell, J, Biotechnology and Bioengineering, 2007, 97(1), 170-181 (transformation of yeast). Examples of enzymes which can be used to produce FPP in a genetically engineered organism are provided in, for example, WO2013064411 or in Schalk et al (2013) J. Am. Chem. Soc. 134, 18900-18903.To prepare the biochemically produced sandalwood oil of the invention, a genetically engineered organism capable of producing FPP and which expresses a suitable sesquiterpene synthase, cytochrome P450 and CPR is prepared. We provide detailed information in the examples herein of the preparation of such a genetically engineered organism, which is in no way limiting to the scope of the present invention.Hence an aspect of the present invention provides a method of preparing a biochemically produced sandalwood oil of the invention comprising; (i) cultivating a genetically engineered organism capable of producing FPP and which expresses a suitable sesquiterpene synthase, cytochrome P450 and CPR, and (ii) isolating the biochemically produced sandalwood oil of the invention.According to a preferred embodiment, the genetically engineered organism capable of producing FPP and which expresses a suitable sesquiterpene synthase, cytochrome P450 and CPR comprises a polypeptide having alpha and beta-santalene synthase activity having at least 55%, preferably at least 60%, preferably at least 65%, preferably at least 70%, preferably at least 75%, preferably at least 80%, preferably at least 85%, preferably at least, 90%, preferably at least, 95%, and even more preferably at least 98% identical to SEQ ID NO: 6. Preferably the genetically engineered organism also comprises a polypeptide having cytochrome P450 activity having at least 55%, preferably at least 60%, preferably at least 65%, preferably at least 70%, preferably at least 75%, preferably at least 80%, preferably at least 85%, preferably at least, 90%, preferably at least, 95%, and even more preferably at least 98% identical to SEQ ID NO: 2. Preferably the genetically engineered organism also comprises a polypeptide having CPR activity having at least 55%, preferably at least 60%, preferably at least 65%, preferably at least 70%, preferably at least 75%, preferably at least 80%, preferably at least 85%, preferably at least, 90%, preferably at least, 95%, and even more preferably at least 98% identical to SEQ ID NO: 4.As used herein, the polypeptide is intended as a polypeptide or peptide fragment that encompasses the amino acid sequences identified herein, as well as truncated or variant polypeptides, provided that they keep their alpha and beta-santalene synthase, cytochrome P450 or CPR activity as defined above and that they share at least the defined percentage of identity with the corresponding fragment of SEQ ID NOs: 6, 2 or 4 appropriate.Examples of variant polypeptides are naturally occurring proteins that result from alternate mRNA splicing events or from proteolytic cleavage of the polypeptides described herein. Variations attributable to proteolysis include, for example, differences in the N- or C- termini upon expression in different types of host cells, due to proteolytic removal of one or more terminal amino acids from the polypeptides of the invention. Polypeptides encoded by a nucleic acid obtained by natural or artificial mutation of a nucleic acid of the invention, as described thereafter, are also encompassed by the invention.Polypeptide variants resulting from a fusion of additional peptide sequences at the amino and carboxyl terminal ends can also be used in the methods of the invention. In particular such a fusion can enhance expression of the polypeptides, be useful in the purification of the protein or improve the enzymatic activity of the polypeptide in a desired environment or expression system. Such additional peptide sequences may be signal peptides, for example. Accordingly, the present invention encompasses methods using variant polypeptides, such as those obtained by fusion with other oligo- or polypeptides and / or those which are linked to signal peptides. Polypeptides resulting from a fusion with another functional protein, such as another protein from the terpene biosynthesis pathway, can also be advantageously be used in the methods of the invention.Preferably the genetically engineered organism capable of producing FPP comprises a polypeptide having alpha and beta-santalene synthase activity having the amino acid sequence as shown in SEQ ID NO: 6, a polypeptide having cytochrome P450 activity having the amino acid sequence as shown in SEQ ID NO: 2 and a polypeptide having CPR activity having the amino acid sequence as shown in SEQ ID NO: 4.The organism or cell is meant to "express" a polypeptide, provided that the organism or cell is transformed to harbor a nucleic acid encoding said polypeptide, this nucleic acid is transcribed to mRNA and the polypeptide is found in the host organism or cell. The term "express" encompasses "heterologously express" and "over-express", the latter referring to levels ofmRNA, polypeptide and / or enzyme activity over and above what is measured in a non-transformed organism or cell. A more detailed description of suitable methods to transform a non-human host organism or cell will be described later on in the part of the specification that is dedicated to such transformed non-human host organisms or cells as specific objects of the present invention and in the examples.The term "transformed" refers to the fact that the host was subjected to genetic engineering to comprise one, two or more copies of each of the nucleic acids required in any of the above-described embodiment. Preferably the term "transformed" relates to hosts heterologously expressing the polypeptides encoded by the nucleic acid with which they are transformed, as well as over-expressing said polypeptides. Accordingly, in an embodiment, the present invention provides a transformed organism, in which the polypeptides are expressed in higher quantity than in the same organism not so transformed. There are several methods known in the art for the creation of transgenic host organisms or cells such as plants, fungi, prokaryotes, or cultures of higher eukaryotic cells. Appropriate cloning and expression vectors for use with bacterial, fungal, yeast, plant and mammalian cellular hosts are described, for example, in Pouwels et al, Cloning Vectors: A Laboratory Manual, 1985, Elsevier, New York and Sambrook et al., Molecular Cloning: A Laboratory Manual, 2nd edition, 1989, Cold Spring Harbor Laboratory Press. Cloning and expression vectors for higher plants and / or plant cells in particular are available to the skilled person. See for example Schardl et al. Gene 61: 1-11, 1987.Methods for transforming host organisms or cells to harbor transgenic nucleic acids are familiar to the skilled person. For the creation of transgenic plants, for example, current methods include: electroporation of plant protoplasts, liposome-mediated transformation, agrobacterium-mediated transformation, polyethylene-glycol-mediated transformation, particle bombardement, microinjection of plant cells, and transformation using viruses.In one embodiment, transformed DNA is integrated into a chromosome of a non-human host organism and / or cell such that a stable recombinant system results. Any chromosomal integration method known in the art may be used in the practice of the invention, including but not limited to recombinase-mediated cassette exchange (RMCE), viral site-specific chromosomal insertion, adenovirus and pronuclear injection.Preferably the genetically engineered organism capable of producing FPP comprises a nucleic acid sequence of SEQ ID NO: 5, a nucleic acid sequence of SEQ ID NO: 1 and nucleic acid sequence as shown in SEQ ID NO: 3.To carry out the invention in vivo, the host organism or cell is cultivated under conditions conducive to the production of the sandalwood oil of the invention. Accordingly, if the host is a transgenic plant, optimal growth conditions are provided, such as optimal light, water and nutrient conditions, for example. If the host is a unicellular organism, conditions conducive to the production of biochemically produced sandalwood oil of the invention may comprise addition of suitable cofactors to the culture medium of the host. In addition, a culture medium may be selected, so as to maximize β-santalene synthesis. Optimal culture conditions are described in a more detailed manner in the following Examples.Non-human host organisms suitable to carry out the method of the invention in vivo may be any non-human multicellular or unicellular organisms. In a preferred embodiment, the non-human host organism used to carry out the invention in vivo is a plant, a prokaryote or a fungus. Any plant, prokaryote or fungus can be used. Particularly useful plants are those that naturally produce high amounts of terpenes. In a more preferred embodiment, the plant is selected from the family of Solanaceae, Poaceae, Brassicaceae, Fabaceae, Malvaceae, Asteraceae or Lamiaceae. For example, the plant is selected from the genera Nicotiana, Solanum, Sorghum, Arabidopsis, Brassica (rape), Medicago (alfalfa), Gossypium (cotton), Artemisia, Salvia and Mentha. Preferably, the plant belongs to the species of Nicotiana tabacum.In a more preferred embodiment the non-human host organism used to carry out the method of the invention in vivo is a microorganism. Any microorganism can be used but according to an even more preferred embodiment said microorganism is a bacteria or yeast. Most preferably, said bacteria is E. coli and said yeast is Saccharomyces cerevisiae.Isolated higher eukaryotic cells can also be used, instead of complete organisms, as hosts to carry out the method of the invention in vivo. Suitable eukaryotic cells may be any non-human cell, but are preferably plant or fungal cells.The method of the aspect of the invention includes a step of isolating the biochemically produced sandalwood oil of the invention.Methods of isolating the biochemically produced sandalwood oil of the invention include the use of flash chromatography or distillation, as would be known to a person skilled in the art. Further information on the isolation processes which can be used are provided in the accompanying examples.Perfume usesAs mentioned above, the invention concerns the use of the sandalwood oil of the invention as a perfuming ingredient. In other words, it concerns a method or a process to confer, enhance, improve or modify the odor properties of a perfuming composition or of a perfumed article or of a surface, which method comprises adding to said composition or article an effective amount of the sandalwood oil of the invention, e.g. to impart its typical note. Understood that the final hedonic effect may depend on the precise dosage and on the organoleptic properties of the sandalwood oil of the invention, but anyway the addition of the sandalwood oil of the invention will impart to the final product its typical touch in the form of a note, touch or aspect depending on the dosage.By “use of the sandalwood oil of the invention” it has to be understood here also the use of any composition containing the sandalwood oil of the invention and which can be advantageously employed in the perfumery industry.Said compositions, which in fact can be advantageously employed as perfuming ingredients, are also an object of the present invention.Therefore, another object of the present invention is a perfuming composition comprising: i) as a perfuming ingredient, the sandalwood oil of the invention as defined above;ii) at least one ingredient selected from the group consisting of a perfumery carrier and a perfumery base; andiii) optionally at least one perfumery adjuvant.By “perfumery carrier” it is meant here a material which is practically neutral from a perfumery point of view, i.e. that does not significantly alter the organoleptic properties of perfuming ingredients. Said carrier may be a liquid or a solid.As liquid carrier one may cite, as non-limiting examples, an emulsifying system, i.e. a solvent and a surfactant system, or a solvent commonly used in perfumery. A detailed description of the nature and type of solvents commonly used in perfumery cannot be exhaustive. However, one can cite as non-limiting examples, solvents such as butylene or propylene glycol, glycerol, dipropyleneglycol and its monoether, 1,2,3-propanetriyl triacetate, dimethyl glutarate, dimethyl adipate 1,3-diacetyloxypropan-2-yl acetate, diethyl phthalate, isopropyl myristate, benzyl benzoate, benzyl alcohol, 2- (2-ethoxyethoxy)-1-ethano, tri-ethyl citrate or mixtures thereof, which are the most commonly used. For the compositions which comprise both a perfumery carrier and a perfumery base, other suitable perfumery carriers than those previously specified, can be also ethanol, water / ethanol mixtures, limonene or other terpenes, isoparaffins such as those known under the trademark Isopar (origin: Exxon Chemical) or glycol ethers and glycol ether esters such as those known under the trademark Dowanol (origin: Dow Chemical Company), or hydrogenated castors oils such as those known under the trademark Cremophor RH 40 (origin: BASF).Solid carrier is meant to designate a material to which the perfuming composition or some element of the perfuming composition can be chemically or physically bound. In general such solid carriers are employed either to stabilize the composition, or to control the rate of evaporation of the compositions or of some ingredients. Solid carriers are of current use in the art and a person skilled in the art knows how to reach the desired effect. However by way of non-limiting example of solid carriers, one may cite absorbing gums or polymers or inorganicmaterial, such as porous polymers, cyclodextrins, wood based materials, organic or inorganic gels, clays, gypsum talc or zeolites.As other non-limiting examples of solid carriers, one may cite encapsulating materials. Examples of such materials may comprise wall-forming and plasticizing materials, such as mono, di- or trisaccharides, natural or modified starches, hydrocolloids, cellulose derivatives, polyvinyl acetates, polyvinylalcohols, proteins or pectins, or yet the materials cited in reference texts such as H. Scherz, Hydrokolloide: Stabilisatoren, Dickungs- und Geliermittel in Lebensmitteln, Band 2 der Schriftenreihe Lebensmittelchemie, Lebensmittelqualitat, Behr's Verlag GmbH & Co., Hamburg, 1996. The encapsulation is a well-known process to a person skilled in the art, and may be performed, for instance, by using techniques such as spray-drying, agglomeration or yet extrusion; or consists of a coating encapsulation, including coacervation and complex coacervation technique.As non-limiting examples of solid carriers, one may cite in particular the core shell capsules with resins of aminoplast, polyamide, polyester, polyurea or polyurethane type or a mixture threof (all of said resins are well known to a person skilled in the art) using techniques like phase separation process induced by polymerization, interfacial polymerization, coacervation or altogether (all of said techniques have been described in the prior art), optionally in the presence of a polymeric stabilizer or of a cationic copolymer.Resins may be produced by the poly condensation of an aldehyde (e.g. formaldehyde, 2,2-dimethoxyethanal, glyoxal, glyoxylic acid or glycolaldehyde and mixtures thereof) with an amine such as urea, benzoguanamine, glycoluryl, melamine, methylol melamine, methylated methylol melamine, guanazole and the like, as well as mixtures thereof. Alternatively one may use preformed resins alkylolated polyamines such as those commercially available under the trademark Urac® (origin: Cytec Technology Corp.), Cymel® (origin: Cytec Technology Corp.), Urecoll® or Luracoll® (origin: BASF).Others resins are the ones produced by the poly condensation of an a polyol, like glycerol, and a polyisocyanate, like a trimer of hexam ethylene diisocyanate, a trimer of isophorone diisocyanate or xylylene diisocyanate or a Biuret of hexamethylene diisocyanate or a trimer of xylylene diisocyanate with trimethylolpropane (known with the tradename of Takenate®, origin: Mitsui Chemicals), among which a trimer of xylylene diisocyanate with trimethylolpropane and a Biuret of hexamethylene diisocyanate are preferred.Some of the seminal literature related to the encapsulation of perfumes by polycondensation of amino resins, namely melamine based resins with aldehydes includes articles such as those published by K. Dietrich et al. Acta Polymerica, 1989, vol. 40, pages 243, 325 and 683, as well as 1990, vol. 41, page 91. Such articles already describe the various parameters affecting the preparation of such core-shell microcapsules following prior art methods that are also further detailed and exemplified in the patent literature. US 4'396'670, to the Wiggins Teape Group Limited is a pertinent early example of the latter. Since then, many other authors have enriched the literature in this field and it would be impossible to cover all published developments here, but the general knowledge in encapsulation technology is very significant. More recent publications of pertinence, which disclose suitable uses of such microcapsules, are represented for example by the article of K. Bruyninckx and M. Dusselier, ACS Sustainable Chemistry & Engineering, 2019, vol. 7, pages 8041-8054.By “perfumery base” what is meant here is a composition comprising at least one perfuming co-ingredient.Said perfuming co-ingredient is not the sandalwood oil of the invention. Moreover, by “perfuming co ingredient” it is meant here a compound, which is used in a perfuming preparation or a composition to impart a hedonic effect. In other words such a co-ingredient, to be considered as being a perfuming one, must be recognized by a person skilled in the art as being able to impart or modify in a positive or pleasant way the odor of a composition, and not just as having an odor.The nature and type of the perfuming co -ingredients present in the base do not warrant a more detailed description here, which in any case would not be exhaustive, the skilled person being able to select them on the basis of his general knowledge and according to the intended use or application and the desired organoleptic effect. In general terms, these perfuming co-ingredients belong to chemical classes as varied as alcohols, lactones, aldehydes, ketones, esters, ethers, acetates, nitriles, terpenoids, nitrogenous or sulphurous heterocyclic compounds and essential oils, and said perfuming co-ingredients can be of natural or synthetic origin.In particular one may cite perfuming co-ingredients which are commonly used in perfume formulations, such as:- Aldehydic ingredients: decanal, dodecanal, 2-methyl-undecanal, 10-undecenal, octanal and / or nonanal and / or nonenal;- Aromatic-herbal ingredients: eucalyptus oil, camphor, eucalyptol, menthol and / or alpha-pinene;- Balsamic ingredients: coumarin, ethylvanillin and / or vanillin;- Citrus ingredients: dihydromyrcenol, citral, orange oil, linalyl acetate, citronellyl nitrile, orange terpenes, limonene, 1-p-menthen-8-yl acetate and / or 1,4(8)-p- menthadiene;- Floral ingredients: methyl dihydrojasmonate, linalool, citronellol, phenylethanol, 3-(4- tert-butylphenyl)-2-methylpropanal, hexylcinnamic aldehyde, benzyl acetate, benzyl salicylate, tetrahydro-2-isobutyl-4-methyl-4(2H)-pyranol, beta ionone, methyl 2- (methylamino)benzoate, (E)-3-methyl-4-(2,6,6-trimethyl-2-cyclohexen-1-yl)-3-buten-2-one, (1E)-1-(2,6,6-trimethyl-2-cyclohexen-1-yl)-1 -penten-3-one, 1 -(2,6,6-trimethyl- 1 ,3-cyclohexadien-1 -yl)-2-buten-1 -one, (2E)-1-(2,6,6-trimethyl-2-cyclohexen-1-yl)-2-buten-1-one, (2E)-1-[2,6,6-trimethyl-3-cyclohexen- 1 -yl] -2-buten- 1 -one, (2E)- 1 -(2,6,6-trimethyl- 1 -cyclohexen- 1 -y l)-2-buten- 1 -one, 2,5-dimethyl-2-indanmethanol, 2,6,6-trimethyl-3-cyclohexene- 1 -carboxylate, 3 -(4,4-dimethyl- 1 -cyclohexen- 1 -yl)propanal, hexyl salicylate, 3,7-dimethyl- l,6-nonadien-3-ol, 3-(4-isopropylphenyl)-2- methylpropanal, verdyl acetate, geraniol, p-menth-1-en-8-ol, 4-(1,1-dimethylethyl)-1- cyclohexyle acetate, 1,1-dimethyl-2-phenylethyl acetate, 4-cyclohexyl-2-methyl-2- butanol, amyl salicylate , high cis methyl dihy droj asmonate, 3-methyl-5-phenyl-1-pentanol, verdyl proprionate, geranyl acetate, tetrahydro linalool, cis-7-p-menthanol, propyl (S)-2-(1,1-dimethylpropoxy)propanoate, 2-methoxynaphthalene, 2,2,2- trichloro- 1-phenylethylacetate, 4 / 3 -(4-hydroxy-4-methylpentyl)-3 -cyclohexene- 1- carbaldehyde, amylcinnamic aldehyde, 8-decen-5-olide, 4-phenyl-2-butanone, isononyle acetate, 4-(1,1- dimethylethyl)-1-cyclohexyl acetate, verdyl isobutyrate and / or mixture of methylionones isomers;- Fruity ingredients: gamma-undecalactone, 2,2,5-trimethyl-5-pentylcyclopentanone, 2-methyl-4-propyl-1,3-oxathiane, 4-decanolide, ethyl 2-methyl-pentanoate, hexyl acetate, ethyl 2-methylbutanoate, gamma-nonalactone, allyl heptanoate, 2-phenoxyethyl isobutyrate, ethyl 2-methyl-1,3-dioxolane-2-acetate, 3-(3,3 / 1,1 -dimethyl-5-indanyl)propanal, diethyl 1,4-cyclohexanedicarboxylate, 3-methyl-2-hexen-1-yl acetate, 1-[3,3-dimethylcyclohexyl]ethyl [3-ethyl-2-oxiranyl] acetate and / or diethyl 1,4-cyclohexane dicarboxylate;Green ingredients: 2-methyl-3-hexanone (E)-oxime, 2, 4-dimethyl-3 -cyclohexene- 1-carbaldehyde, 2-tert-butyl-1 -cyclohexyl acetate, styrallyl acetate, allyl (2-methylbutoxy)acetate, 4-methyl-3-decen-5-ol, diphenyl ether, (Z)-3-hexen-1-ol and / or 1-(5,5-dimethyl-1-cyclohexen-1-yl)-4-penten- 1 -one,- Musk ingredients: 1,4-dioxa-5,17-cycloheptadecanedione, (Z)-4-cyclopentadecen-1-one, 3-methylcyclopentadecanone, 1 -oxa- 12-cyclohexadecen-2-one, 1 -oxa- 13 -cyclohexadecen-2-one, (9Z)-9-cycloheptadecen- 1 -one, 2- { 1 S)-1 -[(1R)-3, 3-dimethy Icy cl ohexyl] ethoxy} -2-oxoethyl propionate 3-methyl-5-cyclopentadecen-1-one, 1,3, 4,6,7, 8-hexahydro-4, 6, 6,7,8, 8-hexamethyl-cyclopenta-g-2-benzopyrane, (1S,rR)-2-[1-(3',3'-dimethyl-1'-cyclohexyl)ethoxy]-2-methylpropyl propanoate, oxacyclohexadecan-2-oneand / or (1S,l'R)-[1-(3',3'-dimethyl-1'-cyclohexyl)ethoxycarbonyl]methyl propanoate, ;- Woody ingredients: 1-[(1RS,6SR)-2,2,6-trimethylcyclohexyl]-3-hexanol, 3,3-dimethyl-5-[(1R)-2,2,3-trimethyl-3-cyclopenten-1-yl]-4-penten-2-ol, 3,4'-dimethylspiro[oxirane-2,9'-tricyclo[6.2.1.02'7]undec[4]ene, (1-ethoxyethoxy)cyclododecane, 2,2,9,11-tetramethylspiro[5.5]undec-8-en-1-yl acetate, 1-(octahydro-2,3,8,8-tetramethyl-2-naphtalenyl)-1-ethanone, patchouli oil, terpenes fractions of patchouli oil, clearwood®, (1'R,E)-2-ethyl-4-(2',2',3'-trimethyl-3'-cyclopenten-1'-yl)-2-buten-1-ol, 2-ethyl-4-(2,2,3-trimethyl-3-cyclopenten-1-yl)-2-buten-1-ol, methyl cedryl ketone, 5-(2,2,3-trimethyl-3-cyclopentenyl)-3-methylpentan-2-ol, 1-(2,3,8,8-tetramethyl-1,2,3,4,6,7,8,8a-octahydronaphthalen-2-yl)ethan-1-one and / or isobornyl acetate;- Other ingredients (e.g. amber, powdery spicy or watery): dodecahydro-3a,6,6,9a-tetramethyl-naphtho[2,1-b]furan and any of its stereoisomers, heliotropin, anisic aldehyde, eugenol, cinnamic aldehyde, clove oil, 3-(1,3-benzodioxol-5-yl)-2-methylpropanal, 7-methyl-2H-1,5-benzodioxepin-3(4H)-one, 2,5,5-trimethyl-1,2,3,4,4a,5,6,7-octahydro-2-naphthalenol, 1-phenylvinyl acetate, 6-methyl-7-oxa-1-thia-4-azaspiro[4.4]nonan and / or 3 -(3 -isopropyl- 1-phenyl)butanal,A perfumery base according to the invention may not be limited to the above mentioned perfuming co-ingredients, and many other of these co-ingredients are in any case listed in reference texts such as the book by S. Arctander, Perfume and Flavor Chemicals, 1969, Montclair, New Jersey, USA, or its more recent versions, or in other works of a similar nature, as well as in the abundant patent literature in the field of perfumery. It is also understood that said co-ingredients may also be compounds known to release in a controlled manner various types of perfuming compounds, also known as properfume or profragrance. Non-limiting examples of suitable properfume may include 4-(dodecylthio)-4-(2,6,6-trimethyl-2-cyclohexen-1-yl)-2-butanone, 4-(dodecylthio)-4-(2, 6, 6-trimethyl- 1-cy cl ohexen-1-yl)-2-butanone, trans-3- (dodecylthio)- 1 -(2,6,6-trimethyl-3 -cyclohexen- 1 -yl)- 1 -butanone, 2-phenylethyl oxo(phenyl)acetate or a mixture thereof.
Claims
CLAIMS1. A biochemically produced sandalwood oil comprising at least 85% santalol and bergamotol and 1% or less cis-lanceol, wherein the oil has one or more of the following features:i) 5 % or less alpha- santalal;ii) 5% or less farnesol;iii) 0.5% or less spirosantalol.
2. The sandalwood oil of claim 1 wherein the at least 85% santalol and bergamotol comprises 37-65% alpha- santalol, 13-37% beta- santalol and 1 to 35% bergamotol.
3. The sandalwood oil of claims 1 or 2 wherein the ratio of cis- alpha- santalol to trans-alpha-santalol is 90: 1 or less.
4. The sandalwood oil of any of the previous claims wherein the alpha- santalal is 90% or more trans- alpha- santalal.
5. The sandalwood oil of any of the previous claims wherein the oil comprises 0-1% cis-beta- sinensol.
6. The sandalwood oil of any of the previous claims comprising:i) 50-60% alpha- santalolii) 20-35% beta- santaloliii) 5% or less alpha- santalaliv) 5% or less farnesolv) 0.5% or less spirosantalolvi) 4-10% bergamotolvii) 0-5% cis-beta- sinensolviii) 5% or less epi-beta-santalol7. The sandalwood oil of any of the previous claims comprising:i) 54%-59% alpha- santalolii) 25.1%-30% beta- santaloliii) 0.7% - 3% alpha- santalaliv) 1% -2.3% farnesolvi) 6.3%- 7.2% bergamotolvii) 0.6% - 1.4% cis-beta- sinensolviii) l%-2% epi-beta- santalol8. The sandalwood oil of any of the previous claims wherein the oil is microbially produced.
9. A method of preparing the biochemically produced sandalwood oil of any of claims 1 to 8 comprising: (i) cultivating a genetically engineered organism capable of producing FPP and which expresses a suitable sequiterpene synthase, cytochrome P450 and CPR, and (ii) isolating the biochemically produced sandalwood oil of the invention.
10. The sandalwood oil of any of the previous claims wherein the oil is encapsulated within a matrix material.
11. A perfuming composition comprising:i) the sandalwood oil of any of the previous claims,ii) at least one ingredient selected from the group consisting of a perfumery carrier and a perfumery base; andiiii) optionally at least one perfumery adjuvant.
12. A perfumed consumer product comprising a sandalwood oil of any of the previous claims or a perfuming composition as defined in claim 11.
13. The perfumed consumer product according to claim 12, wherein the perfumery consumer product is a perfume, a fabric care product, a body-care product, a cosmetic preparation, a skin-care product, an air care product or a home care product, or wherein the perfumery consumer product is a fine perfume, a splash or eau de perfume, a cologne, a shave or an after-shave lotion, a liquid or solid detergent, a fabric softener, a fabric refresher, an ironing water, a paper, a bleach, a carpet cleaners, curtain-care products a shampoo, a coloring preparation, a color care product, a hair shaping product, a dental care product, a disinfectant, an intimate care product, a hair spray, a vanishing cream, a deodorant or antiperspirant, hair remover, tanning or sun product, nail products, skin cleansing, a makeup, a perfumed soap, shower or bath mousse, oil or gel, or a foot / hand care products, a hygiene product, an air freshener, a “ready to use” powdered air freshener, a mold remover, furnisher care, wipe, a dish detergent or hard-surface detergent, a leather care product, a car care product.
14. The sandalwood oil of any of the previous claims for use in the treatment of a microbial infection, an inflammatory condition and / or increase skin moisturizing, or for use in the treatment of acne, eczema, psoriasis, seborrheic or atopic dermatitis.
15. An arthropod control composition comprising the sandalwood oil of any of the previous claims.
